Presentation

FluoGuide’s primary focus is to maximise surgical outcomes in oncology. The lead asset, FG001, is based on the proprietary uPAR technology and designed to improve surgical precision by illuminating cancer cells intraoperatively. uPAR (urokinase-type plasminogen activator receptor) is expressed extracellularly in most types of solid malignancies such as breast, prostate, brain and head and neck cancers. It is currently being evaluated in Ph1/2 trials in patients with high-grade glioma and NSCLC undergoing surgeries.

Recent highlights
In March, FluoGuide carried out a directed share issue raising approximately SEK 25M. In the same month, Fluoguide awarded a grant together with Rigshospitalet (DK) to conduct a Ph2 trial with FG001 in less aggressive brain cancers. Also in the same month, Fluoguide received approval from the Danish Medicines Agency to initiate Ph2 trial with FG001 in NSCLC. In April, Fluoguide announced positive top line result from the first part of the ongoing clinical Ph1/2 trial with FG001 in high-grade glioma surgeries. FG001 has been shown safe and well tolerated in 40 patients, with early evidence of efficacy demonstrating strong illumination of tumours intraoperatively, which was later confirmed by histopathology data. The optimal dose and time of FG001 administration has been decided to be 36 mg administered the evening before surgery.

Outlook
The company aims to commence Ph1/2 trial in patients with less aggressive brain cancer undergoing neurosurgeries in H2 2022. The company also expects more data from the two ongoing trials with FG001 in high-grade glioma and NSCLC by the end of 2022.